摘要
最近的实验性缺血性卒中研究证实,胞磷胆碱既具有神经保护作用,又可通过增高外周血内皮祖细胞数量、促进血管和神经发生、增强神经元可塑性发挥神经修复作用。尽管迄今样本量最大的多中心随机安慰剂对照试验——国际胞磷胆碱治疗急性卒中试验(International Citicoline Trial on Acute Stroke,ICTAS)得出了中性结果,但亚组分析显示胞磷胆碱治疗较未接受rtPA溶栓治疗的安慰剂治疗有效,而且无明显不良反应。因此,将其应用于急性缺血性卒中患者,尤其是未能接受溶栓治疗的患者是合理的。
Recent experimental ischemic stroke studies have shown that citicoline can not only have neuroprotective effect, but also play the effect of nerve repair by increasing the number of endothelial progenitor cells in peripheral blood, promoting angiogenesis and neurogenesis, and enhancing neuronal plasticity. So far, although the multicenter randomized placebo controlled trials with the largest sample size- the International Citicoline Trial on Acute Stroke (ICTAS) has obtained a neutral result, the subgroup analyses have shown that citicoline treatment is more effective than placebo of not receiving rtPA thrombolytic therapy, and does not have obvious adverse reaction. Therefore, its application in patients with acute ischemic stroke is reasonable, particularly in those not receiving thrombolytic therapy.
出处
《国际脑血管病杂志》
北大核心
2014年第9期700-703,共4页
International Journal of Cerebrovascular Diseases
关键词
卒中
脑缺血
胞苷二磷酸胆碱
神经保护药
Stroke
Brain Ischemla
Cytidine Diphosphate Choline
Neuroprotective Agents